NHS London Branded Medicines - Tranche B - September 2023

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2 year
Value
£231M
Sector
HEALTH
Published
11 Aug 2023
Delivery
01 Sep 2023 to 31 Aug 2025
Deadline
17 Apr 2023 12:00

Concepts

Location

Geochart for 1 buyers and 36 suppliers

1 buyer

36 suppliers

Description

NHS London Branded Medicines - Tranche B - September 2023 Offer reference number: CM/PHR/22/5677 CM/PHR/22/5677/01 - NHS Framework for London Branded Medicines - Tranche B. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months CM/PHR/22/5677/02 - NHS Framework for London Branded Medicines - Annual Tranche. Period of framework: 1 September 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Award Detail

1 Thornton & Ross (Huddersfield)
  • Value: £231,083,000
2 Biogen (Maidenhead)
  • Value: £231,083,000
3 Glaxosmithkline (London)
  • Value: £231,083,000
4 Accord (Barnstaple)
  • Value: £231,083,000
5 Celltrion Healthcare (Slough)
  • Value: £231,083,000
6 Sandoz (Camberley)
  • Value: £231,083,000
7 Zentiva Pharma (Felsted)
  • Value: £231,083,000
8 Takeda (London)
  • Value: £231,083,000
9 Orifarm (Hemel Hempstead)
  • Value: £231,083,000
10 Merck Sharpe & Dohme (London)
  • Value: £231,083,000
11 Teva (Castleford)
  • Value: £231,083,000
12 CST Pharma (Walsall)
  • Value: £231,083,000
13 Roche Products (Welwyn Garden City)
  • Value: £231,083,000
14 Astrazeneca (London)
  • Value: £231,083,000
15 Kent Pharma (Ashford)
  • Value: £231,083,000
16 Pfizer (Tadworth)
  • Value: £231,083,000
17 Mylan (Hatfield)
  • Value: £231,083,000
18 Abbvie (Maidenhead)
  • Value: £231,083,000
19 Janssen Cilag (High Wycombe)
  • Value: £231,083,000
20 Eli Lilly (Basingstoke)
  • Value: £231,083,000
21 Ipsen (Slough)
  • Value: £231,083,000
22 Organon Pharmaceuticals (London)
  • Value: £231,083,000
23 Almirall (Uxbridge)
  • Value: £231,083,000
24 Sun Pharma (Uxbridge)
  • Value: £231,083,000
25 Aventis Pharma (Reading)
  • Value: £231,083,000
26 Gedeon Richter (London)
  • Value: £231,083,000
27 Merck Serono (Feltham)
  • Value: £231,083,000
28 Novartis Pharmaceuticals (London)
  • Value: £231,083,000
29 Galapagos Biotech (Uxbridge)
  • Value: £231,083,000
30 Novo Nordisk (London Gatwick Airport)
  • Value: £231,083,000
31 Typharm (Norwich)
  • Value: £231,083,000
32 Sobi Swedish Orphan Biovitrum (Great Abington)
  • Value: £231,083,000
33 Gilead Sciences (High Holborn)
  • Value: £231,083,000
34 Neon Healthcare (Hertford)
  • Value: £231,083,000
35 Bayer (Reading)
  • Value: £231,083,000
36 Ucb Pharma (Slough)
  • Value: £231,083,000

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

Document No. 03 - Framework Agreement and Terms and Conditions - CM_PHR_22_5677 Document No. 03 - Framework Agreement and Terms and Conditions - CM_PHR_22_5677.docx FTS Opportunity Notice - London Tranche B - 2023S 000-007212 FTS Opportunity Notice - London Tranche B - 2023S 000-007212.pdf Document No. 10 - Pharmacy Purchasing Points List CM_PHR_22_5677 Document No. 10 - Pharmacy Purchasing Points List CM_PHR_22_5677.xlsx Parties Appointed to the framework CM-PHR-22-5677 Parties Appointed to the framework CM-PHR-22-5677.xlsx Transparency Documents - LONDON - 5677-01 Transparency Documents - LONDON - 5677-01.pdf Transparency Documents - LONDON - 5677-02 Transparency Documents - LONDON - 5677-02.pdf

Reference

Domains